Literature DB >> 21881374

Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer?

Hidefumi Kita1, Yuji Shiraishi, Kenichi Watanabe, Kazuharu Suda, Kouki Ohtsuka, Yoshihiko Koshiishi, Tomoyuki Goya.   

Abstract

PURPOSE: We examined the influence of inflammatory cytokine levels on postoperative early recurrence in patients who underwent curative lung cancer surgery.
METHODS: In 107 patients who underwent curative pulmonary resections for non-small cell lung cancer (NSCLC) from November 2007 to June 2008, we measured serum interleukin-6 (IL-6) levels preoperatively, and on postoperative day (POD) 0, 1, and 2. Between July 2009 and August 2009, 1 year after the date of enrollment of the last patient, we investigated survival status of each patient and identified a group with recurrence.
RESULTS: Among 107 patients, 29 patients developed recurrence with a mean follow-up of 18.1 months (range 14 to 21). P-stage was significantly more advanced in the recurrence group than in the non-recurrence group (p = 0.005). Serum IL-6 levels on POD 1 were significantly higher in the recurrence group than in the non-recurrence group (p = 0.007). In Cox's proportional hazards regression, P-stage and serum IL-6 levels on POD 1 were significant independent predicting factors for postoperative early recurrence (p = 0.006, p = 0.003).
CONCLUSIONS: The higher the serum IL-6 levels on POD 1, the higher the risk of early postoperative recurrence, even when curative pulmonary resection can be accomplished in lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881374     DOI: 10.5761/atcs.oa.10.01627

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  15 in total

1.  IDO is a nodal pathogenic driver of lung cancer and metastasis development.

Authors:  Courtney Smith; Mee Young Chang; Katherine H Parker; Daniel W Beury; James B DuHadaway; Hollie E Flick; Janette Boulden; Erika Sutanto-Ward; Alejandro Peralta Soler; Lisa D Laury-Kleintop; Laura Mandik-Nayak; Richard Metz; Suzanne Ostrand-Rosenberg; George C Prendergast; Alexander J Muller
Journal:  Cancer Discov       Date:  2012-07-19       Impact factor: 39.397

2.  Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.

Authors:  Zhaoxia Qu; Fan Sun; Jingjiao Zhou; Liwen Li; Steven D Shapiro; Gutian Xiao
Journal:  Cancer Res       Date:  2015-06-29       Impact factor: 12.701

Review 3.  Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Authors:  George C Prendergast; Courtney Smith; Sunil Thomas; Laura Mandik-Nayak; Lisa Laury-Kleintop; Richard Metz; Alexander J Muller
Journal:  Cancer Immunol Immunother       Date:  2014-04-08       Impact factor: 6.968

4.  Interleukin-6 cytokine: a multifunctional glycoprotein for cancer.

Authors:  Paul Zarogoulidis; Lonny Yarmus; Kaid Darwiche; Robert Walter; Haidong Huang; Zhigang Li; Bojan Zaric; Kosmas Tsakiridis; Konstantinos Zarogoulidis
Journal:  Immunome Res       Date:  2013-08-12

5.  A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Bríd M Ryan; Sharon R Pine; Anil K Chaturvedi; Neil Caporaso; Curtis C Harris
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

6.  VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.

Authors:  T Fleitas; V Martínez-Sales; V Vila; E Reganon; D Mesado; M Martín; J Gómez-Codina; J Montalar; G Reynés
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

7.  Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma.

Authors:  Claire L Meaney; Adriana Zingone; Derek Brown; Yunkai Yu; Liang Cao; Bríd M Ryan
Journal:  Oncotarget       Date:  2017-06-20

8.  17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression.

Authors:  Quanfu Huang; Zheng Zhang; Yongde Liao; Changyu Liu; Sheng Fan; Xiao Wei; Bo Ai; Jing Xiong
Journal:  J Exp Clin Cancer Res       Date:  2018-07-03

9.  Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.

Authors:  Xiaohong Tan; Julian Carretero; Zhao Chen; Jishuai Zhang; Yanxiao Wang; Jicheng Chen; Xiubin Li; Hui Ye; Chuanhao Tang; Xuan Cheng; Ning Hou; Xiao Yang; Kwok-Kin Wong
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

Review 10.  Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis.

Authors:  Bodo E Lippitz; Robert A Harris
Journal:  Oncoimmunology       Date:  2016-05-11       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.